Certified Emergency Nurse (CEN) Practice Test

Which treatment is recommended for patients with Hemophilia C?

1. DDAVP

2. Replacement factor VII

3. Topical thrombin

4. IVIG

The correct answer is: Topical thrombin

The correct treatment for patients with Hemophilia C is topical thrombin. Hemophilia C, which is also known as Factor XI deficiency, is characterized by a deficiency in Factor XI, leading to abnormal bleeding tendencies, particularly after surgery or trauma. Topical thrombin is used as an adjunctive treatment for controlling bleeding in patients with mild to moderate hemophilia C because it directly aids in the coagulation process at the site of a bleed. It promotes hemostasis by converting fibrinogen to fibrin, thereby helping to form a stable clot. While DDAVP is effective for Hemophilia A by increasing the release of Factor VIII, it is not relevant for Hemophilia C, as it doesn't affect Factor XI levels. Replacement factor VII is specifically relevant for patients with Hemophilia A or B, particularly for those who have developed inhibitors, and does not serve the needs of those with Hemophilia C. IVIG (Intravenous Immunoglobulin) is not indicated in the management of hemophilia but may be used in different clinical scenarios where immune modulation is required. Therefore, topical thrombin is a pertinent and effective treatment choice specifically aimed at addressing the bleeding associated with Hemophilia C.